Physician profile
Howard Cooper
NPI 1720021223
$1,195.83
in general payments reported to CMS, 2019-2025
23 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $77.37 · 2022: $52.68 · 2023: $144 · 2024: $202 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $292.12 | 2022-2025 | Darzalex, Balversa, Erleada |
| Incyte Corporation | $151.05 | 2019-2025 | Monjuvi |
| Janssen Biotech, INC. | $131.91 | 2019-2023 | Tecvayli |
| Daiichi Sankyo INC. | $116.63 | 2024-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals Lp | $61.06 | 2019 | |
| Pfizer INC. | $54.31 | 2019 | |
| Merck Sharp & Dohme LLC | $51.67 | 2019 | |
| Seagen INC. | $50.15 | 2019-2023 | Tukysa |
| Abbvie INC. | $45.17 | 2019-2023 | Venclexta |
| Bayer Healthcare Pharmaceuticals INC. | $37.97 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $31.05 | 2019 | |
| Genzyme Corporation | $19.03 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.57 | 2019 | |
| Lilly USA, LLC | $17.29 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.31 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $14.20 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.19 | 2019 | |
| Amgen INC. | $13.82 | 2020 | |
| Emd Serono, INC. | $12.89 | 2020 | |
| Karyopharm Therapeutics INC. | $12.86 | 2020 | |
| Genentech USA, INC. | $12.35 | 2019 | |
| Celgene Corporation | $11.95 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $11.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.